0001626199-24-000030.txt : 20240207 0001626199-24-000030.hdr.sgml : 20240207 20240207161202 ACCESSION NUMBER: 0001626199-24-000030 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240202 ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Other Events FILED AS OF DATE: 20240207 DATE AS OF CHANGE: 20240207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC. CENTRAL INDEX KEY: 0001626199 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 208969493 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37449 FILM NUMBER: 24604411 BUSINESS ADDRESS: STREET 1: 188 EAST BLAINE ST., SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-788-4545 MAIL ADDRESS: STREET 1: 188 EAST BLAINE ST., SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Nivalis Therapeutics, Inc. DATE OF NAME CHANGE: 20150211 FORMER COMPANY: FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20141121 8-K 1 alpn-20240202.htm 8-K alpn-20240202
0001626199false00016261992024-02-022024-02-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 2, 2024
  
ALPINE IMMUNE SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3744920-8969493
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)		(IRS Employer
Identification No.)
188 East Blaine Street, Suite 200
Seattle, Washington 98102
(Address of Principal Executive Offices, including zip code)
(206) 788-4545
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading SymbolName of each exchange on which registered
Common Stock, par value $0.001 per shareALPNThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐


Item 3.02. Unregistered Sales of Equity Securities.

Item 8.01. Other Events.
During the period from November 30, 2023 to February 2, 2024, Alpine Immune Sciences, Inc. (the “Company”) issued an aggregate of 5,656,567 shares of its common stock, $0.001 par value per share (the "Common Stock"), pursuant to the exercise of outstanding warrants to purchase shares of Common Stock, as described in more detail below. The warrants were issued by the Company in multiple transactions previously reported on Current Reports on Form 8-K filed with the Securities and Exchange Commission on January 16, 2019, July 24, 2020, September 15, 2021 and November 8, 2023. Following these issuances, the total number of shares of the Company’s Common Stock outstanding as of February 5, 2024 is 65,536,031.
On November 30, 2023, the Company issued 14,735 shares of its Common Stock, or the First Warrant Net Exercise Shares, to warrant holders upon their exercise of outstanding warrants to purchase an aggregate of 148,257 shares of the Company’s Common Stock, pursuant to a net exercise mechanism under the warrants. Each warrant had an exercise price of $12.74 per share. The issuances of the First Warrant Net Exercise Shares were exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 3(a)(9) thereof as an exchange with an existing security holder where no commission or other remuneration is paid or given for soliciting such exchange.
On December 1, 2023, the Company issued 25,005 shares of its Common Stock, or the Second Warrant Net Exercise Shares, to warrant holders upon their exercise of outstanding warrants to purchase an aggregate of 222,387 shares of the Company’s Common Stock, pursuant to a net exercise mechanism under the warrants. Each warrant had an exercise price of $12.74 per share. The issuances of the Second Warrant Net Exercise Shares were exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 3(a)(9) thereof as an exchange with an existing security holder where no commission or other remuneration is paid or given for soliciting such exchange.
On December 6, 2023, the Company issued 334,676 shares of its Common Stock, or the Third Warrant Net Exercise Shares, to warrant holders upon their exercise of outstanding warrants to purchase an aggregate of 334,697 shares of the Company’s Common Stock, pursuant to a net exercise mechanism under the warrants. Each warrant had an exercise price of $0.001 per share. The issuances of the Third Warrant Net Exercise Shares were exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 3(a)(9) thereof as an exchange with an existing security holder where no commission or other remuneration is paid or given for soliciting such exchange.
On December 11, 2023, the Company issued 145,251 shares of its Common Stock, or the First Warrant Cash Exercise Shares, to warrant holders upon their exercise of outstanding warrants to purchase an aggregate of 145,251 shares of the Company’s Common Stock for an aggregate total of $1,850,497.74 paid in cash. Each warrant had an exercise price of $12.74 per share. The issuances of the First Warrant Cash Exercise Shares were exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof as a transaction by an issuer not involving a public offering.
On December 20, 2023, the Company issued 50,759 shares of its Common Stock, or the Fourth Warrant Net Exercise Shares, to warrant holders upon their exercise of outstanding warrants to purchase an aggregate of 177,909 shares of the Company’s Common Stock, pursuant to a net exercise mechanism under the warrants. Each warrant had an exercise price of $12.74 per share. The issuances of the Fourth Warrant Net Exercise Shares were exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 3(a)(9) thereof as an exchange with an existing security holder where no commission or other remuneration is paid or given for soliciting such exchange.
On December 21, 2023, the Company issued 4,930 shares of its Common Stock, or the Fifth Warrant Net Exercise Shares, to warrant holders upon their exercise of outstanding warrants to purchase an aggregate of 14,823 shares of the Company’s Common Stock par value per share, pursuant to a net exercise mechanism under the warrants. Each warrant had an exercise price of $12.74 per share. The issuances of the Fifth Warrant Net Exercise Shares were exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 3(a)(9) thereof as an exchange with an existing security holder where no commission or other remuneration is paid or given for soliciting such exchange.
On December 27, 2023, the Company issued 135,602 shares of its Common Stock, or the Sixth Warrant Net Exercise Shares, to warrant holders upon their exercise of outstanding warrants to purchase an aggregate of 385,470 shares of the Company’s Common Stock, pursuant to a net exercise mechanism under the warrants. Each warrant had an exercise price of $12.74 per share. The issuances of the Sixth Warrant Net Exercise Shares were exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 3(a)(9) thereof as an exchange with an existing security holder where no commission or other remuneration is paid or given for soliciting such exchange.
On December 28, 2023, the Company issued 25,271 shares of its Common Stock, or the Seventh Warrant Net Exercise Shares, to warrant holders upon their exercise of outstanding warrants to purchase an aggregate of 74,130 shares of the


Company’s Common Stock, pursuant to a net exercise mechanism under the warrants. Each warrant had an exercise price of $12.74 per share. The issuances of the Seventh Warrant Net Exercise Shares were exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 3(a)(9) thereof as an exchange with an existing security holder where no commission or other remuneration is paid or given for soliciting such exchange.
On December 29, 2023, the Company issued 26,177 shares of its Common Stock, or the Eighth Warrant Net Exercise Shares, to warrant holders upon their exercise of outstanding warrants to purchase an aggregate of 74,441 shares of the Company’s Common Stock, pursuant to a net exercise mechanism under the warrants. Each warrant had an exercise price of $12.74 per share. The issuances of the Eighth Warrant Net Exercise Shares were exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 3(a)(9) thereof as an exchange with an existing security holder where no commission or other remuneration is paid or given for soliciting such exchange.
January 9, 2024, the Company issued 74,885 shares of its Common Stock, or the Ninth Warrant Net Exercise Shares, to warrant holders upon their exercise of outstanding warrants to purchase an aggregate of 222,390 shares of the Company’s Common Stock, pursuant to a net exercise mechanism under the warrants. Each warrant had an exercise price of $12.74 per share. The issuances of the Ninth Warrant Net Exercise Shares were exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 3(a)(9) thereof as an exchange with an existing security holder where no commission or other remuneration is paid or given for soliciting such exchange.
On January 11, 2024, the Company issued 145,251 shares of its Common Stock, or the Second Warrant Cash Exercise Shares, to warrant holders upon their exercise of outstanding warrants to purchase an aggregate of 145,251 shares of the Company’s Common Stock for an aggregate total of $1,850,497.74 paid in cash. Each warrant had an exercise price of $12.74 per share. The issuances of the Second Warrant Cash Exercise Shares were exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof as a transaction by an issuer not involving a public offering.
On January 12, 2024 the Company issued 70,792 shares of its Common Stock, or the Tenth Warrant Net Exercise Shares, to warrant holders upon their exercise of outstanding warrants to purchase an aggregate of 217,875 shares of the Company’s Common Stock, pursuant to a net exercise mechanism under the warrants. Each warrant had an exercise price of $12.74 per share. The issuances of the Tenth Warrant Net Exercise Shares were exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 3(a)(9) thereof as an exchange with an existing security holder where no commission or other remuneration is paid or given for soliciting such exchange.
On January 19, 2024, the Company issued 1,234,636 shares of its Common Stock, or the Third Warrant Cash Exercise Shares, to warrant holders upon their exercise of outstanding warrants to purchase an aggregate of 1,234,636 shares of the Company’s Common Stock for an aggregate total of $15,729,262.64 paid in cash. Each warrant had an exercise price of $12.74 per share. The issuances of the Third Warrant Cash Exercise Shares were exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof as a transaction by an issuer not involving a public offering.
On January 26, 2024 the Company issued 158,054 shares of its Common Stock, or the Eleventh Warrant Net Exercise Shares, to warrant holders upon their exercise of outstanding warrants to purchase an aggregate of 459,600 shares of the Company’s Common Stock, pursuant to a net exercise mechanism under the warrants. Each warrant had an exercise price of $12.74 per share. The issuances of the Eleventh Warrant Net Exercise Shares were exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 3(a)(9) thereof as an exchange with an existing security holder where no commission or other remuneration is paid or given for soliciting such exchange.
On January 30, 2024 the Company issued 10,664 shares of its Common Stock, or the Twelfth Warrant Net Exercise Shares, to warrant holders upon their exercise of outstanding warrants to purchase an aggregate of 29,652 shares of the Company’s Common Stock, pursuant to a net exercise mechanism under the warrants. Each warrant had an exercise price of $12.74 per share. The issuances of the Twelfth Warrant Net Exercise Shares were exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 3(a)(9) thereof as an exchange with an existing security holder where no commission or other remuneration is paid or given for soliciting such exchange.
On February 2, 2024, the Company issued 3,199,879 shares of its Common Stock, or the Thirteenth Warrant Net Exercise Shares, to warrant holders upon their exercise of outstanding warrants to purchase an aggregate of 3,200,000 shares of the Company’s Common Stock, pursuant to a net exercise mechanism under the warrants. Each warrant had an exercise price of $0.001 per share. The issuances of the Thirteenth Warrant Net Exercise Shares were exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 3(a)(9) thereof as an exchange with an existing security holder where no commission or other remuneration is paid or given for soliciting such exchange.



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: February 7, 2024
  ALPINE IMMUNE SCIENCES, INC.
 By: /s/ Paul Rickey
 Name: Paul Rickey
 Title: Senior Vice President and Chief Financial Officer


 EX-101.SCH 2 alpn-20240202.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 alpn-20240202_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 4 alpn-20240202_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover Page
Feb. 02, 2024
Cover [Abstract]  
Entity Central Index Key 0001626199
Amendment Flag false
Document Type 8-K
Document Period End Date Feb. 02, 2024
Entity Registrant Name ALPINE IMMUNE SCIENCES, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-37449
Entity Tax Identification Number 20-8969493
Entity Address, Address Line One 188 East Blaine Street
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98102
City Area Code 206
Local Phone Number 788-4545
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ALPN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ("!1U@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " " @4=8?MA3R.\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)^GZ!T,W%\63@N""XBTDL[O!I@G)2+MO;QMWNX@^@,?,_/+- M-S"MB=*$A,\I1$SD,%^,ONNS-''-]D11 F2S1Z]S/27ZJ;D-R6N:GFD'49L/ MO4-H.+\&CZ2M)@TSL(H+D:G6&FD2:@KIB+=FPNPI@Z@%,#5/ MC(>Q:^$,F&&$R>?O MJ%6*I_8DL'V#$Y9K>DAF&HAU7)33L(>'MZ?"GK5J[/ MI'N#TZ_L)!TBKMEI\NOJ[G[SP%3#F\N*-Q6_V31""B&O;M]GUQ]^9V$?K-NZ M?VQ\$E0M_+H+]0502P,$% @ @(%'6)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" " @4=8?!MFN6L$ M$0 & 'AL+W=OS+PJ1Z>#4.' MQ(4V,ML' T'&Q>Y(W_8#<1C@'PD(]@%!R;U[44EY1PT=]I7<$F6?!C5[4G:U MC 8X+NRL1$;!70YQ9CB6KTR1.4Q WS6@9Z^Z\3[V=A<;'(F]9\L+X@5G)/"" M\/MP%S JEJ!B"4J]2Y3EG]%2&P6S]6\3T4XA;%:P*7RC2J4C8&_G$WILX<27/\_Q.T/%[/00K MK+!"5&P$BR2!/T/N4[IN@L'C5S35#.&XJCBN4)T[&17*G,[C*]V_+[NF*[/B5_GMB:VPP'R!G-&LEP MG='#?#J;D.GCXU1&=D.AM?()C="K-["N94Q%+E4E'KGF#8MF!U+.16-,+APLSV. M@@L$7@<#J:N$C]O[@XQA3.8;*3!W:Q&Y[G;/PZOP"B.J"X*/F_:SXL8P 0.3 M9878.YMNI,*%VK8:?ET!?-R^(YGRF!LNUN01TEMQFC;RX"IM/$%= +>* MG<

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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.alpineimmunesciences.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports alpn-20240202.htm alpn-20240202.xsd alpn-20240202_lab.xml alpn-20240202_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "alpn-20240202.htm": { "nsprefix": "alpn", "nsuri": "http://www.alpineimmunesciences.com/20240202", "dts": { "inline": { "local": [ "alpn-20240202.htm" ] }, "schema": { "local": [ "alpn-20240202.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "alpn-20240202_lab.xml" ] }, "presentationLink": { "local": [ "alpn-20240202_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.alpineimmunesciences.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "alpn-20240202.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "alpn-20240202.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001626199-24-000030-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001626199-24-000030-xbrl.zip M4$L#!!0 ( ("!1U@.@3[Y@!$ &"? 1 86QP;BTR,#(T,#(P,BYH M=&WM7>MSXC@2_[Y_A8J]NTFJ#/@-)@E768;98W>&I$+F=NN^7 E;!-48VRN+ M!.ZOOY9L\WX8)A-@AJNZG8"M1[?ZUR^UQ/4_1P,?/1,6TS"X>:>5U'>(!&[H MT>#IYMUMI]%JO?MG_:?K/H?7X-4@KM$1ORGT.8]JY?++RTMIU&5^*61/91KX M-"!__O+PLR :80[]E7=75HJH7-;TP[:08$W>N(_A<>@J?-_:C646U M6C2TK)]13.?Z>#'D5'15U$XW3'>.#34?PQ(72%#\W"G4K_L$>_7K >$8B?9%\M>0/M\4&F' 2<"+C^,( MFKG)IYL")R->EC,MUW_ZZ:=K3KE/ZMB/@B*PSX3EUJ_+R9?7Y:3K;NB-Z]<> M?48Q'_ODIN#1./+QN!:$ 8$)T%%-O$A8\B?U/!+(/^%Y>S@@C+K)^"/^0'HW M!;<(0A#@@>B)T%HS@.' @=PWXK\,CH=S(N(.K=%'I%72_451 )6[>!R=?E MN5YW&.1V0 (/_L\_^/AITKE1J/>P'Y.E?LOSA##2(PS 1>(5_!>R48NEN,+( M2,I*C0/7;PHQ'42^6#3Y79^)BKXN-Z]E7\[U'P)[0RSZ!3#+^'G-2 M%_0(-2&$9_'99)K>FE>S)]GG;)#R'-T9DR9<*<_(71FD,Q%1P1WJ6%U/K3@] M3'JVJ77UJF4[N&ICV_!ZAF5;_Q7LXPB 272;6+/D[Z6:I,Z$CBS!MAEU>BX># 6;C*_C/$PS"PZAF M0O>"K"+VZ5-0UG5?[OJ@=\*/;P@/KCVKM'.@!A;),7 M]! .EQHEI*N6Z1QPVNK"M,V5T_['SYJM7F73Y+CKDVP* MW9 !$(LP$Q]',:EE?UQEMB*Q>479*,-!-^0\'-0L&!S\&$Y=[*=D2HJ3QRD( M3:-4L2L"AQSPSKULX!2B)9A?>?E[IUIRU-6/U)(FOR_+_ECV,"78B'A!M@%" M!+DW!? LYFE-9Z]%',6A3STD%N JPI[PP&HJ@@>3_LN2[M=>-6V/55O6>E.= M)#L\%IA_N'OXA/(;^/>A.Q3V/7%W$OL.6KY:_'W9N)]A=H;9]P^S?*8(;.E# ML_V('IKW=P^/1V\Y[X)>U/=3[O8P-FDG$4$!)@@$\_A&O>?!-<0!=]$6SHH?'Q3$,723!)-X# MJT*Z; BN.-(5)"*11>. =A*>LVX^1=U\>)M^>$CK9BY([YK%>2!/-!:I/]Z& M)QGNC$+]]N-]J]U$K4^?/L,_G4:KV6XT.PIJM1NE(W;05G/EHCF"J%X2+_0; MFQ"-<(SBB+@BA>(A&B#*8P2:'=0=6V^69A;?6K/V9T6SNZ*9\/FMV>=O>UZ,16FE-EF0XC-Y> ME:K[&)A6X(8,_$>YJ]3AX/(UPF' V;@1>O/^H$C BBPT)Q$+GT4_4T?0!&>5 M^/@%LQ6I_U1+<^^55NT[7(4/U"?P'_=X)/>DG5+#%OA;=VPK0E"R>$+"7\1 M]=]!-,W0;Q!,QQZ5.8'#N9#YY@Y>XYPF6W .#X"4R4(?8B4;X6! 8U'((+?6 MA'I!B?Q?'E!Y')0EK8<.:@XB/QP3)IDRKQU0.RQ=+N-^R?<]7,XH7RBUJYJ\ M]3Q&XCC]YR/TIV4JLE*H:]4J:N*8HU]\#(]0AS-"^**Z5';(.ZT;5<]&K1;J MG2$%/:2KZLD%LGORH0%_WK''\&7B4#G !8(Y]Y?\J;V9+;7[';L'YXW*RI>< MOIVFSNZO+N?W]IO-?0C#^?^A4>)GID-IA;I3U40EP[$L?+Z]M8N4*I&]N&? M7AIA'S5'Q!UR^DS070_T#(D5!(_\H=":Z'\T F9Y)%<:XZA4S$7^)1>"?]N(27Z89O=Q]?PS!LMSWPV#!<]:,0KU2K19-R[1RR]'1\GJ: /S' MSU5=JUS%B!.?1()N%$C"9Z4* C"\1:R.A;1V^?;H8?T!5"1XPFV9F&0H_9B" M'?C>0PVYS>2ACM"IZ*.PE;CTY+JBLJ.M36CTB?M%[F'B""QPQ*B( MQ+KA"'6)'[X(01,/A?PE#:K%WU&/^@+R- ;\V$:T!%3!'7OLG. MC_W*&S]6(F=OG:JV17YW-936)6;UDE7=+?F[%I1V2=.H6BF.N1AZ),$?*9NI7IBH>I"%%M< M:!74^/" =$,MP8LK8NH?2O8Z8+YYA/%Y-VS,,X)8RN.AX3M(9*5LTBN%$F#%,T+-Y]( MIN_NF>T^CI 5_&Q=M?/U?)''(_,-^2/XH3N4DQM=M'KH_C M^.LLR/&1N) I^4ZH>F189KH[XT$W]+^[W>Q\3&BGE;)2>$EFZ4$_O?0I?#-5 M8J_D=AX?!W:(P!/E/M;TK@3]Q)>L%NK")P6N=7CH?E%0A!EZQOZ0H+^I)575 M4"0.??>/JZCM-)B>HC0!Z83CCJQ;;Y^YN:<(9SY]F!^ZUY705^" MH]+&L8?_2L0C"$/&P@0RM3M=#R^;+I ML3(#70A#6[F2"<_L92J/*43BF(+8.$R"-+U;U%?TM>JLVJ13$;!-V\UT6SH2 M]C=7LS)Q/O8Z)_1:*8J]*G(RW9B2^'!@78A6[T-J!#U M!2LA1I=V#_L (.)#K 0 "D(9.0UC(M\"KJ=[E.(B(RJCJ>1B$L%<.98_%H._ M4!A:@#$ VN )(\\TAG8 2QRX0C2PZXH:=?&RN,7'P\R+D]U);W78EIUHO<"3 MV&T6=*5989TLX)H%F[_0) H34FJ,^%B4^BQ=<3)-B2_+?/IO;PB12[C. O1=R##FK8?\'C6!C0U[ZGYO&IG)@4_:U278^'@(,@#TXJFE>,CSA$D0$"=!0.;Z3V*!21"0C%F8C1D*E\J _:@/J!=Z8SF0]%I",2NXQV$U=D$,+X'N&8 M^DE)2 D)QV[2YPM(?49W-ZGV2+DB6P]]3B-P0:3NQ6Z:11::-:D2R8Z0BQ"R M,61,Y)R3,J98?"7J3E!:<@(O20V]X,0 D5.=.BT_%ZU_PX%<6,T6*ZLY"OIM M"&.*)1:WX2G0#7@T4B T2WZGR>XF8E)-I*0$\\AJ46#T."$8)T(AIL-##M8A M*8H3+)TR=X8?DS*Z68;/+12632;RF$S)%)ZC;2F682NJH9T0$J6!OPN64:?, MBTDB/)JI5 QK 2'SLADF3O4'RF*._D@D$.;)1;UK(OD=V5H1DIY**.J'OD=8 MC(81= 3-*=L-*(M@ULRJHEN5'=9X'JD8W L^G<* "-&E\6!F!R6;1PDU19IE M0@F6JF72- +_3D[I;QH83W.J+Q*(3F0TF^-6OB5@AOX'$4\49N9A2:=I;>5% M&H](Y8$'TME25B:QA1]TX5R*/AB!5CB)B3+TI@X8? BO%TRS\>SN2O3A!3[XF;*JX- MD-(M155S00H6* 3%=RA,Z;JN&-53Q-1VQIU!=7J@LC> RC!,Q:[8>5#UV*?L M<*"2$W6."U0+V>TUH-K*MS.F3@]3VB9+I9D6.%7:[MY? \?]-W;_%F>ZU<47 M*SK731(N2".C5"U5,9V*M#5"#B!H4*2"EST-J-BP4T2,. M$H%@,H='@^?0?Y:!$?38!4C :#TB(OM3!H*^*0H"::A83BXR148 M=>2EO(=#5<54-&,15.?=[#U_=61>; \DI2>A$K>+_5DIGJ!2=#8I15N!^!/E MT8I-T?]!E:)I[I(M.A98;>?;&56G@:JL"L+)REM6 K$M%J=W2E<#Z@V/:23 M(7<*G5-TW;?R[8?'T^N"8_&7+E:# Z'U+NIQPOENIJY)VP#I';94%C:Q3V%/ MY1@V57*P[;RK\E902(LW5QHW5:DXN=)2CP<-H$',E6K%.D';MI5O/[QM.T%$ M;?(7-447U27&'F4P;V]=5LSUJ_;L+:4"T:ENZR7[F]J7[7P[FYDGB*H%=CCH?W07CJ^^P[[1^;=\^?GYH=G+=0: ?3'/>+YRC9>2O M(67R_L/97-^F6S.4M.'.&SJXJ&X0T#>H)$<=A7#= F*88&2,( VLCL\Y/V0 7'>M[^&(U\&_92O15][":%=,G:\%WW] M#>O:ENL,[DL\ MEML7UU]N>XA;@]3LI^UK4T^YDOUX_)R]?;6;?+_-+5\Y2=WY&L;][S@[-=J= M8[Z:>?7O"&[^W?6M=\'NK]SLMWHMIY[Y<:1T[P5:03L3PQX5\;^,:SM0_ETN MYQ$IG=44E>,RNL=#'SU0]PL9[W.IZQFNWP=0";AG0RII_[%35UYH?4 MOJO5?DV*#_C3#V>8GV&>7D]_-LPG0%2'!#1DZ-]B2^*>D9B*'2AY?UVC3TD/ M?9A<6YK\"##[VEN63R@[7^Z&WAC^Z?.!7_\_4$L#!!0 ( ("!1UC+,.G2 M=P( *$' 1 86QP;BTR,#(T,#(P,BYXPRUM M$]2DTEI5FI1M5==J?9N,.1"K8#/;-.F_G^U@I?2R%6D/XP',.=]W[@=.SW9- MC1Y *B;X,HBG48" 4U$P7BV#VYM+/ _.5I/)Z0>,[SY=K]&%H%T#7*-S"41# M@;9,;Y#> /HAY#U[(.BJ)KH4LL%XY6CGHGV4K-IHE$3)S,.\5F9I$1=01#FF M99GB&4TISND\PDEZ?!0=131*YB4(PF44)GD$)F) BQ>D1.3XF M4.1)DCNC.Y4INH&&(),:5]E.+8.-UFT6AMOM=KI-IT)681)%<7CW9?W=08,> M6S-^/T#O#BI6SZ &P'CP)JFXZ H,Y4$-:6B"6WJD;D%B&@M M6=YIN#0UNH"2=+5>!AW_U9&:E0P*TX :;(D'@"=J360%^BMI0+6$PL@ 5A.$ M;(U8TPJI$7_53%^D>+%8A#N;=8#V-5T+2K0;E3>+Y/#8'G&[E01A.]R M.S3$N-+$)##&MWG#GO27M::@2G%7F!$-O#,1W\-I5^B%YOQRHBX1T8DE:+^RSR%K10M M2,U /=TJ9V CH5P&=K>PG]J?K82IB<1#7C@8ML"JC0=09HML6(9G OS7[@BE0G,RF^O/[_O4^.\ M'\C>@_=10,DXAL\)STQU"HIO?.7.S]O=DWO('XB4 MU+2KQ_,.8;U)ZX6^JOW6A<.UV[\_64TGV._[:O(;4$L#!!0 ( ("!1UCV MXY[SBPH !-A 5 86QP;BTR,#(T,#(P,E]L86(N>&ULU5QM;]LX$O[> M7\'+?;D#=FJ)HMZ*-HM>MET4EVV#)L4N[G P^)H(:TN!K#3)OS]2MA,KEFQ1 MLE4M B2./1H^\UC/<(:D_?;GA_D,?9?Y(LG2=R?N:^<$R91G(DFOWYU\N_H( MTO?T;P!__^GJ.?LGXW5RF!3K+)2VD0/=)<8.*&XE^S_(_D^\473\M4G MTT529ZC=NI,_?CN_Y#=R3B%)%P5-N1E@D;Q9E$^>9YP6)>M[<:%&"_,?K,W M/ 4N!L]]_; 0)Z>O$%K2D6+9'X[D^OG;G*IZMW.\KSBU:",#4HW,"C_WC38I ?\ M ^$MMK$> %P9[N=#8=S%Z>>#P;W2&4(>'_#&,+TA+V^H#ZD8ZMY]&JHW].,C M/M1MD15T-L!M\3S,!N29>>). W-+V6G^E<3AD341#($)0?,2"88:"N$P%CGD>H M[TM'JFGQ=$]/90K?+M?#EV/L'N#$(K*B0:&Y7&1W.7^>V^:SN@E+SU5F=HLF MJ1YW<4M7%VB4IA!8 C]=8T1KD,B@?#MYCJ<#B;.C4S,;%2L9KR"9F3(@RU^& MGO&]H3_+:J%1EW$O)']]G7V?Z$MU_-@S#\ \*-74Z'"R];:]S]TZ4%/4)8+F>NJM2: VOO.Q>PJ*69R2DE, M/>+ZX D5 HD]K=F(^Q!BPETE6$!CUU:X:^=C$VT)"F4*N?@?[)]H#==>M4_L MM5=L%TZ.K%9;.CK)]67>2T6DA&1.6XW6CC VH:Y HBK*]CJMIW&_ M6'N3XVM!>Q67& 9<@A4EP!P2'1=:T2H%PF_5AA5Y'6Q6V+\<8FT"5D5,'\$RI1:YK1 M"CDRT-NKMPWO^S5]8#:/K/1#$&F5!BSHZ90W@NA M[Z-%Z?=+?I%GWQ,=SM3E^B?P]10?.KKH=B0'&DH%3AB&7L!BEX:>75ZI'VBD M"64%=D,!:\"V::2!W[;YHS]KPR2.#H1U2!>[V>B1)QH<#YP@=H>WG1GVV-NG MA(M:B_F;,:GQ>).YE=F6RO_HI1N*;7P?=NTL&^PL:4&C1?X!F"T1(R6D%&)N7UVV$OU_@QQ2 */G"5Z<6>5*-J2 MTBE9['4^6,)H&^9FTFA]C7WB6)_F>CK \(M.25,N?(*%4.!CKHN(B'H04:4[ ME# * AQ'),)^VVQ1.\+84L33H;8E2J1A(H.S?5JH)W)_+NA-SY$3@#4S5J+? M&7TGI==['$S>.P/:U/1N0WLAGV7?9?Z>+8J<\J+%?5>Q']']5N)"_UTC^]]A M[K/::#O=7U5/@]U7M0%LWD_U!EV;RP]SF5\GZ?6O>79?W.C)YY:FCU,5*S<* M&0;EA]2<=G(@CG1OZ7%.0M?ADGO,KK>L'6=LD\.J4UIC14NP:(76MJ^LI[9M M6]F;L&&Z2ENN.K24.YGHT5'6^QVXH=P9W'8_N=N\=SNYV=U@S/V0<0:,A"$0 M12.(6!0!51@3SJE/HM8YH'F8L:6 K3;H(+UCKZ[Q+](O'KU1/%*+.(;FT*XM M/$Q#>)G-$IX4.IG\I@O2/*&S::"H9%(I$"$.@% 2 (U% H+(IA+ QFWEORV M^[%)_1DA6D.T."FYS=Y^8??CY,B"MJ'#[J1D8]3=SDINNQONM&1C*)7SDLU6 M'=H]LXJ<2UKN:<8AI69GQQR4]("P.(9(L]-UPOLD5! M9_]);I?'.,R'3R7V03A>#"00+L2N'T+@!)RZ6/]1K3\ U#S,V(3XB_Q5IU^V,V6&M#:]Q>K;?NOD=RI2^= MNA&)!&,81.!%0'A$(#+'FR,J<$P]K/2/[=:(<3PVB3^M^QMP]ML@)5?M=S]L M&1AJTV-G\)UV.C8C[;7!43H:?%]C$W[==D;E=7NIO=<^A/'S<4:OIX''",72 M!<^. ,A#2"8!H MJ0'S2 1AI(@7.-*4N7:5[8L1QB;"5:6V0HE*F$CCM*UF7Q+9MI#M0<\P-6Q[ M9CH4KPW1]ZA;7WH+6C'4?:EHFX/^ZT0;/G_, M(M%V4(TK1#6F705^11\^"3V3)VKU4?K53*)8(%U!??!\Z0 )J0+J8 =XJ)S MX1[7K:V=S!M&&JG8-5I4A=MQ=FXBN*WL#T#;,.*W9ZQ# MC#1H\TT.1YX&2P M)\#ME+#O@IXS_^K/>9)*=RJ(D,)\J4UHOL"4$!P =6,*0>C$2CJ^=)5E;UTS MRD@3PM/VZ:U0AUK(&Z$K7P%5 :Z:Z5P)U3/2O!2I>?TPU4!=8 M8SU0:WPXX>.I\'WI48Y!ZK( M.X#B$.*P?49$2)VL'ZZK_#Q7TKX5_=9?^'C M'L*WHNM'"G\74P<1/CZ*\/&/%SZV$3[N+?RO\CHQG\-(B_+K33W',_M54HO< M%T!X[)E%./W+84H0Y=* 6G8 U0%&*O=GD);?$5M+8EM]=Z=F&&FW9:6#H.M# M[Z'E%PX'EG%].-L*;K!K$N\FXUKN?YZ^6C^3++]#__35_P%02P,$% @ M@(%'6)(DN3WD!@ '#, !4 !A;'!N+3(P,C0P,C R7W!R92YX;6S5FUM3 MXT86Q]_Y%%[OZS;N^X4:2+%D9HL*R5 SI)+:%U5?;55DR26) ;[]'@FSV+IJY"7R]/YSSUJUJ[B[)>J_BW_8F?7 MA6U35:\1.NMONZ@V#W6^7+4SBBG?-MO^6I^P0$(,V"&?$D/<,X^V73 M?SV=K]IV<[)8W-W='=^[NCBNZN6"8LP6V];SI^;WS]K?L;XU,<8L^E]_;]KD M+S6$;LGBUQ^O/OM57%N4ETUK2]\9:/*3IK]X57G;]JK_Z;AFK[;HOJ%M,]1= M0H0B1H[OFS _.YK-'N6HJR)^BFG6O?_\Z7+'I"TV>1GS]?JVC(W/(?JQ.?;5 M>M$U7EQ4 ,>U779#[[MJ'S;Q=-[DZTWQ^[55'=/I'#HJ41=C#"_= /[^Q\V+ M/\:RJ6,# /6^7\&%ISXZ:^/'%>_;6 ).O>];BT7E=QH5G?)5O;VSL"X6_=4L MQ#SK>SYW35M;WV8X\"2"=2@Y*8'.&)&63"/,1 B)*ZFD'.$(RF]C :GJ",>-?X7S>[Z\77$SVL_J^H0:YALMG9M[9]%?Q?S MIQ:+C:VA(^17>1&V=Z>Z6N\C>FVU3RT?(P;CGL_ _13K.H:KQX"]ZF7O8@MS M<>Q;CH'A'.;HT,W3'PJ[S)2CD3'"D,#!(YX0U#Q(;J3"QHR#8,317>E^%[V)-E//D$,Q1LH2@3X$"4R(B8D';!&,FP\H3O M)?0[9@[CAD)F)CH-1*!$A@_<\C9Q)&B M5G A++58[6']W[4Z" 4Q711&*SD)$BXACZLW5=T+_QGTCQ?5+>QH'BZJ$#/K MG-96@R?!1,0E)@"VAAS".JH",=VRMP!#8?\B+^=+MV MLW\9 M0*L\Y8_EB2='B-%4,HE1Z HTW& &C@B!% NP.A(KG?9[0.$5\X.XT%/G8A_: M3@*2\Q @!,W3VU5>1I)9GP)QCB..E0-IDH(-,X\(6 [P8[9*>V1D#H('JG26NP/C&^L M#Z-CPM7+O4D[)42NJZ:UQ;_S39]242DUI2Q")AX3[)<<09I".NZE-S8Z)D-R M^P-DQ_8P/"9&HYOUSNMH^W$SV!(QH@4*SBN8]S!%S@B"F"$I)6NB MI",?T7UE;1@ $RYSOEFZ X>\>UQ>7*^J5-UY@*?TNJR'W>YN7R1]C@U+DM,FT MYF@%$K3+E;$PR#%M44@),ZDL\=&,0N&YS6$<3+A<.5+& T-P7<>.X.Y@4/_L MMCOX4W],,([,Z,1M\ 818;JM#)-(NP3ZA 1]:(5-'+-WV,"@F7*O)R+,1# -EPG7+O4I\ MZ 4E^EM8%!\(=3=Y6\1,:2LQ-0S!T'$GBD(N!(P4X<$JJX618=QR\HW%8:>F M)ERL'"7A@<-_4]ONQ//GA[6KBHP:@G%( BD9.>)""D#6$T0-),$J*.?%N.-R M.^:&!7["]1/_KW]WYERV7LCWEPGA)DO0:92"$E]L(APWV")2]))E2* MQ(\[,/N2U6$,3+CJ.%K*250;WZ]CO024_U57=^T*%K>-+1\R@Y-5-!ADN84L MV5&&G"(2L11XM%1IJ?9QA/I%X\/ F'R]<;RP>^/CW>*9E%=PX>SHZ8?NI?MG MBK.C_P!02P$"% ,4 " " @4=8#H$^^8 1 !@GP $0 M@ $ 86QP;BTR,#(T,#(P,BYH=&U02P$"% ,4 " " @4=8RS#ITG<" M "A!P $0 @ &O$0 86QP;BTR,#(T,#(P,BYX\XL* 380 %0 @ %5% 86QP M;BTR,#(T,#(P,E]L86(N>&UL4$L! A0#% @ @(%'6)(DN3WD!@ '#, M !4 ( !$Q\ &%L<&XM,C R-# R,#)?<')E+GAM;%!+!08 1 ! $ 0! J)@ ! end XML 15 alpn-20240202_htm.xml IDEA: XBRL DOCUMENT 0001626199 2024-02-02 2024-02-02 0001626199 false 8-K 2024-02-02 ALPINE IMMUNE SCIENCES, INC. DE 001-37449 20-8969493 188 East Blaine Street Suite 200 Seattle WA 98102 206 788-4545 false false false false Common Stock, par value $0.001 per share ALPN NASDAQ false